where the method comprises preparing a solution or dispersion of a salt or crystalline form of Compound 1 described herein in a pharmaceutically acceptable solvent or mixture of solvents, and administering the resulting solution or dispersion in a therapeutically effective amount to a subject having the disease.

[0032a] In some embodiments, there is provided the use of a therapeutically effective amount of (a) a compound as defined herein or (b) a pharmaceutical composition comprising a compound as defined herein and one or more pharmaceutically acceptable excipients, in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

[0032b] In some embodiments, there is provided the use of a solution or dispersion of a compound as defined herein in the manufacture of a medicament for treating a disease characterized by apoptotic dysfunction and/or overexpression of an anti-apoptotic Bcl-2 family protein.

[0033] Additional embodiments of the invention, including particular aspects of those provided above, will be found in, or will be evident from, the detailed description that follows.

BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Fig. 1 is a PXRD scan of Compound 1 anhydrate designated pattern A.

[0035] Fig. 2 is a PXRD scan of Compound 1 anhydrate designated pattern B.

[0036] Fig. 3 is a PXRD scan of Compound 1 hydrate designated pattern C.

[0037] Fig. 4 is a PXRD scan of Compound 1 hydrate designated pattern D.

[0038] Fig. 5 is a calculated PXRD pattern of Compound 1 dichloromethane solvate designated pattern E.

[0039] Fig. 6 is a PXRD scan of Compound 1 ethyl acetate solvate designated pattern F.

[0040] Fig. 7 is a PXRD scan of Compound 1 ethyl acetate solvate designated pattern G.

[0041] Fig. 8 is a calculated PXRD pattern of Compound 1 acetonitrile solvate designated pattern H.

[0042] Fig. 9 is a PXRD scan of Compound 1 acetonitrile solvate designated pattern I.

[0043] Fig. 10 is a PXRD scan of Compound 1 acetone solvate designated pattern J.

[0044] Fig. 11 is a calculated PXRD pattern of Compound 1 hydrochloride designated pattern K.

[0045] Fig. 12 is a PXRD scan of Compound 1 hydrochloride hydrate designated pattern L.

[0046] Fig. 13 is a PXRD scan of Compound 1 sulfate designated pattern M.

[0047] Fig. 14 is a PXRD scan of Compound 1 tetrahydrofuran solvate designated pattern N.

DETAILED DESCRIPTION

[0048] The term "free base" is used for convenience herein to refer to Compound 1 parent compound as distinct from any salt thereof, while recognizing that the parent compound,